



# REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

[www.elsevier.es/rgmx](http://www.elsevier.es/rgmx)



## ORIGINAL ARTICLE

# Inflammatory map of the gastroduodenal mucosa in patients with upper gastrointestinal symptoms. The role of *H. pylori* infection<sup>☆</sup>

M.R. Caballero-Plasencia<sup>a</sup>, A.M. Caballero-Mateos<sup>b,\*</sup>, A.M. Caballero-Plasencia<sup>b</sup>

<sup>a</sup> Servicio de Aparato Digestivo, Hospital Clínico San Cecilio, Granada, Spain

<sup>b</sup> Universidad de Granada, Granada, Spain

Received 10 August 2021; accepted 5 October 2021

### KEYWORDS

Chronic gastritis;  
Duodenitis;  
*Helicobacter pylori*;  
Functional dyspepsia

### Abstract

**Introduction and aim:** The gastric mucosa has been studied since the pre-*Helicobacter pylori* (*H. pylori*) era, but the complete descriptions of the stomach and duodenum have been anecdotal, and those of the distal duodenum, exceptional. Our aim was to evaluate the different epidemiologic characteristics and the gastroduodenal inflammatory status in patients with upper gastrointestinal symptoms.

**Materials and methods:** We studied 138 patients divided into: the non-ulcer group (functional dyspepsia [n = 77] and GERD [n = 27]) and the ulcer group (peptic ulcer [n = 13] and duodenal ulcer [n = 21]). Ten biopsy samples (2 from the corpus, 3 from the antrum, 3 from the proximal duodenum, and 2 from the distal duodenum) were taken in each patient for histologic and/or microbiologic study.

**Results:** The prevalence of dyspepsia, functional dyspepsia, and *H. pylori* was 80.4%, 69.4%, and 82.6%, respectively. The frequency of superficial chronic gastritis in the corpus was significantly higher in the ulcer group vs. the non-ulcer group, whereas there was more chronic atrophic gastritis in the antrum in the ulcer group ( $P < 0.05$ ). Duodenitis was significantly more frequent in the ulcer group vs. the non-ulcer group, in both the proximal and distal duodenum. Pangastroduodenitis was a significant finding in the ulcer group. In both groups, chronic gastritis (corpus and antrum) and duodenitis (proximal and distal) were significantly related to the presence of *H. pylori*. Proximal duodenitis is not an uncommon finding in functional dyspepsia (37.7%) and is twice as frequent as distal duodenitis (16.9%).

<sup>☆</sup> Please cite this article as: Caballero-Plasencia MR, Caballero-Mateos AM, Caballero-Plasencia AM. Mapa inflamatorio de la mucosa gastroduodenal en pacientes con síntomas gastrointestinales altos. Protagonismo de la infección por *H. pylori*. Rev Gastroenterol Méx. 2022. <https://doi.org/10.1016/j.rgmx.2021.10.001>

\* Corresponding author. Hospital Clínico San Cecilio, Av. Ilustración s/n, Granada. Telephone: +34626464145. E-mail address: [ogy1492@hotmail.com](mailto:ogy1492@hotmail.com) (A.M. Caballero-Mateos).

**Conclusions:** The ulcer group presented with a gastroduodenal inflammatory map different from that of the non-ulcer group and was characterized by a higher frequency of superficial chronic gastritis in the corpus, chronic atrophic gastritis in the antrum, and a very high frequency of proximal duodenitis.

© 2022 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## PALABRAS CLAVE

Gastritis crónica;  
Duodenitis;  
*Helicobacter pylori*;  
Dispepsia funcional

## Mapa inflamatorio de la mucosa gastroduodenal en pacientes con síntomas gastrointestinales altos. Protagonismo de la infección por *H. pylori*

### Resumen

**Introducción y objetivo:** La mucosa gástrica ha sido estudiada desde la época anterior al *Helicobacter pylori*, pero son anecdóticas las descripciones completas del estómago y duodeno, y excepcionales las del duodeno distal. El objetivo fue evaluar diversas características epidemiológicas y el estado inflamatorio gastroduodenal en pacientes con síntomas gastrointestinales altos.

**Material y métodos:** Estudiamos a 138 pacientes divididos en: grupo no ulceroso (dispepsia funcional, n = 77 y ERGE, n = 27) y grupo ulceroso (úlcera gástrica, n = 13 y úlcera duodenal, n = 21). En cada paciente se tomaron 10 biopsias (2 en el cuerpo; 3 en el antro, 3 en el duodeno proximal y 2 en el duodeno distal) para estudio histológico o microbiológico.

**Resultados:** La prevalencia de dispepsia, dispepsia funcional y *H. pylori* fue del 80.4%, 69.4% y 82.6%, respectivamente. En el cuerpo se apreció una significativa mayor frecuencia de gastritis crónica superficial en el grupo ulceroso que en el no ulceroso; sin embargo, en el antro, el grupo ulceroso mostró más gastritis crónica atrófica ( $p < 0.05$ ). La duodenitis fue significativamente más frecuente en el grupo ulceroso, tanto en el duodeno proximal como en el distal. La pangastritis fue un hallazgo significativo en el grupo ulceroso. Todos los grupos mostraron gastritis crónica (cuerpo y antro) y duodenitis (proximal y distal) relacionadas significativamente con la presencia de *H. pylori*. La duodenitis proximal no es un fenómeno extraño en la dispepsia funcional (37.7%), con una frecuencia que duplica a la de duodenitis distal (16.9%).

**Conclusiones:** El grupo ulceroso presentó un mapa inflamatorio gastroduodenal diferente al del grupo no ulceroso, caracterizado por una mayor frecuencia de gastritis crónica superficial en cuerpo, atrófica en antro y muy frecuente duodenitis proximal.

© 2022 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction and aim

In the pre-*Helicobacter pylori* (*H. pylori*) era, Scandinavian groups carefully studied the gastric mucosa in the general population. They established the concepts of chronic gastritis (CG) of the corpus and antrum, demonstrated its increase with age (in frequency, extension, and inflammatory intensity), according to the sequence of normal mucosa, superficial chronic gastritis (SCG), and chronic atrophic gastritis (CAG), and confirmed its frequent patchy distribution and extension from the pylorus to the cardia, as well as pangastritis. They reported the prevalence of CG-corpus (41-62%) and CG-antrum (60-68%), and CAG-corpus (17-37%) and CAG-antrum (28-34%).<sup>1-4</sup> Once *H. pylori* infection was discovered, it was confirmed as the main non-autoimmune cause of CG, peptic ulcer, duodenal ulcer, and gastric adenocarcinoma.<sup>1</sup> Since then, there have been countless publications related to those findings, but very few describe a complete inflammatory map of the gastroduodenal tract.

The evaluation of the duodenum is of great interest, given its recent and growing prominence in different processes, its relation to chronic antral gastritis, and the presence of *H. pylori*.<sup>5,6</sup> The aim of the present study was to analyze the gastroduodenal mucosa and its relation to *H. pylori* in patients with upper gastrointestinal symptoms that came to our center to undergo diagnostic gastroscopy.

## Patients and methods

After gastroscopy, 138 patients with upper gastrointestinal symptoms were selected that belonged to 2 diagnostic groups: 1) the non-ulcer group, with the following subgroups: functional dyspepsia (FD) (Rome IV criteria) (n = 77)<sup>7</sup> and gastroesophageal reflux disease (GERD) (Montreal-Lyon criteria) (n = 27)<sup>8</sup> and 2) the ulcer group, with the following subgroups: duodenal ulcer (DU) (n = 21) and peptic ulcer (PU) (n = 13). Patients taking proton-pump inhibitors (PPIs), antibiotics, or nonsteroidal anti-inflammatory drugs

(NSAIDs)/acetylsalicylic acid (ASA) within the last 4 weeks were excluded. Ten biopsy samples were taken from each patient: 2 from the corpus (at 10 cm from the cardia, greater curvature), 2 from the antrum (at 5 cm from the pylorus, greater curvature), 2 from the proximal duodenum (bulb) (D1), and 2 from the distal duodenum (in front of the papilla) (D2), for histologic study (H&E, PAS) and *H. pylori* identification (Giemsa), along with one from the antrum and another from the D1, for microbiologic culture/study. The presence of CG/duodenitis was evaluated through the Whitehead et al. classification for CG<sup>9</sup> and for duodenitis.<sup>10</sup> In short, CG was divided into SCG (reactive changes and inflammatory infiltrate limited to the superficial epithelium and nearby lamina propria) and CAG (reactive changes and inflammatory infiltrate affecting the glandular bed, with atrophy of the tubules; the atrophy was subdivided into mild, moderate, and severe). Duodenitis was divided into 4 grades: grade 0: normal mucosa; grade 1 or mild duodenitis: normal general morphology and superficial epithelium, and only a slight increase in inflammatory cells (lymphocytes, plasma cells, and sometimes polymorphonuclear cells) in the lamina propria; grade 2 or moderate duodenitis: abnormalities in the superficial epithelium and obvious inflammatory infiltrate; and grade 3 or intense or severe duodenitis: superficial epithelial erosions and important inflammatory infiltrate with villous pattern loss. Given the scant inflammatory changes in mild duodenitis (D-1), we included it as normal mucosa and grouped moderate/intense duodenitis (D-2/D-3) in a single group (DD). A patient was considered *H. pylori*-positive when the bacterium was present in a histologic sample and/or the culture was positive in a biopsy sample.

### Statistical analysis

The results were expressed as  $\pm$  standard deviation (SD). Their relationships (differences) were statistically analyzed through the chi-square test (or Fisher's test, when applicable) and the Student's t test. Statistical significance was set at a  $p < 0.05$ .


### Ethical considerations

The present study was approved by the Clinical Research Ethics Committee of Granada (CEIC, Spanish acronym) and all patients signed written statements of informed consent.

### Results

The demographic data and the inflammatory/microbiologic status of the gastroduodenal mucosa are summarized in Table 1. In our study sample, the total prevalence of dyspepsia, FD, and *H. pylori* was 80.4%, 69.4%, and 82.6%, respectively.

**Gastric corpus.** The frequency of normal mucosa (NM), SCG, and CAG was similar in the 4 subgroups, with a scant atrophic component. The frequency of SCG was significantly higher than that of CAG in the ulcer group vs the non-ulcer group ( $p < 0.05$ ) (Table 1).



**Figure 1** a) Gastroduodenal inflammatory map in inverted "V". b) Gastroduodenal inflammatory map in "plateau". CAG: chronic atrophic gastritis; CG: chronic gastritis; DD: duodenitis II + III; D1: proximal duodenum; D2: distal duodenum.

**Gastric antrum.** There was an increase in inflammatory phenomena in the gastric antrum, in all the subgroups, as demonstrated by the clear predominance of CG vs NM. There was also a higher frequency of atrophic phenomena (CAG) vs SCG in the antrum and all the subgroups, but that difference was significant only when the subgroups FD vs DU were compared ( $p < 0.05$ ). When the ulcer group was compared with the non-ulcer group, there were differences between the frequencies of NM vs CAG ( $p < 0.05$ ) and SCG vs CAG ( $p < 0.02$ ) (Table 1). As shown in the graphs, the gastroduodenal inflammatory map of all the subgroups produced an inverted "V", with greater elevation in the subgroups of the ulcer group, given the higher percentage of CG in the antrum. By considering only the presence of CAG in both the corpus and the antrum, the image in Fig. 1a was transformed into an elevation followed by a "plateau" that was descending in the PU subgroup and ascending in the DU subgroup, as a consequence of the higher percentage of DD-D1 in DU vs PU (Fig. 1b).

**Proximal and distal duodenum.** In the duodenum, at both the D1 and D2 levels, there was a higher frequency of DD vs NM in the patients with PU, albeit with no statistical significance when compared with that of the other subgroups. In contrast, in the patients with DU, there were several differences with other subgroups, with respect to the frequency of DD vs NM, at the D1 level (DU vs FD,

**Table 1** Gastroduodenal mucosa in the 138 patients.

Endoscopic diagnosis (n = 138)	% (n)	M/F	Age (years)	Corpus (%)			Antrum (%)			D1 (%)		D2 (%)		<i>H. pylori</i> (%)				
				NM	SCG	CAG	NM	SCG	CAG	NM	DD	NM	DD	(+)	C	A	D1	D2
FD	55.8 (77)	39/38	49.5 ± 15.9	59.7 (46)	31.2 (24)	9.1 (7)	20.7 (16)	39.0 (30)	40.3 (31)	62.3 (48)	37.7 (29)	83.1 (64)	16.9 (13)	77.9 (60)	48.1 (37)	67.0 (52)	71.4 (55)	67.5 (52)
GERD	19.6 (27)	20/7	53.6 ± 15.7	63.0 (17)	18.5 (5)	18.5 (5)	22.3 (6)	33.3 (9)	44.4 (12)	55.5 (15)	44.5 (12)	74.0 (20)	26.0 (7)	74.1 (20)	44.4 (12)	59.2 (16)	62.9 (17)	55.5 (15)
Peptic ulcer (PU)	9.4 (13)	8/5	48.0 ± 14.1	46.1 (6)	46.1 (6)	7.8 (1)	7.8 (1)	23.0 (3)	69.2 (9)	38.5 (5)	61.5 (8)	61.5 (8)	38.5 (5)	100 (13)	92.3 (12)	84.6 (11)	76.9 (10)	69.2 (9)
Duodenal ulcer (DU)	15.2 (21)	19/2	48.8 ± 16.8	57.2 (12)	42.8 (9)	0.0 (0)	14.3 (3)	19.1 (4)	66.6 <sup>a</sup> (14)	23.8 (5)	76.2 (16)	57.1 (12)	42.9 (9)	100 (21)	57.1 (12)	61.9 (13)	61.9 (13)	57.1 (12)
FD + GERD	75.4 (104)	59/45	51.6 ± 15.8	60.6 (63)	27.9 (29)	11.5 (12)	21.2 (22)	37.5 (39)	41.3 (43)	60.6 (63)	39.4 (41)	80.8 (84)	19.2 (20)	76.9 (80)	47.1 (49)	64.4 (67)	69.2 (72)	64.4 (67)
PU + DU	24.6 (34)	27/7	48.4 ± 15.5	52.9 (18)	44.2 <sup>b</sup> (15)	2.9 (1)	11.8 <sup>c</sup> (4)	20.6 (7)	67.6 <sup>d</sup> (23)	29.4 (10)	70.6 (24)	58.8 (20)	41.2 (14)	100 (34)	70.6 (24)	70.6 (24)	67.6 (23)	61.7 (21)


CAG: chronic atrophic gastritis; DU: duodenal ulcer; F: female; FD: functional dysplasia; GERD: gastroesophageal reflux disease; M: male; NM: normal mucosa; PU: peptic ulcer; SCG: superficial chronic gastritis; DD: duodenitis II + III; C: corpus; A: antrum; D1: proximal duodenum; D2: distal duodenum.

<sup>a</sup> SCG vs CAG between FD and DU ( $p < 0.05$ ).

<sup>b</sup> SCG vs CAG between (FD + GERD) and (PU + DU)-( $p < 0.05$ ).

<sup>c</sup> NM vs CAG between (FD + GERD) and (PU + DU)-( $p < 0.05$ ).

<sup>d</sup> SCG vs CAG between (FD + GERD) and (PU + DU)-( $p < 0.02$ ).



**Figure 2** Normal duodenal mucosa and duodenitis.

DD: duodenitis II+III; DU: duodenal ulcer; D1: proximal duodenum; D2: distal duodenum; FD: functional dyspepsia; GERD: gastroesophageal reflux disease; NM: normal mucosa; PU: peptic ulcer.

‡ NM vs DD-D1 between DU and FD,  $p < 0.004$ .

§ NM vs DD-D1 between DU and GERD,  $p < 0.05$ .

# NM vs DD-D2 between DU and FD,  $p < 0.02$ .

**Table 2** Extension of the gastroduodenal inflammation.

Percentage (n)	DF	GERD	PU	DU	FD + GERD	PU + DU
Endoscopic diagnosis (n = 138)	55.8 (77)	19.6 (27)	9.4 (13)	15.2 (21)	75.4 (104)	24.6 (34)
Pangastritis (CG corpus + antrum)	36.4 (28)	25.9 (7)	46.2 (6)	42.9 (9)	33.6 (35)	44.1 (15)
Pangastroduodenitis (CG corpus + antrum + DD)	16.9 (13)	7.4 (2)	30.8 (4)	28.6 (6)	14.4 (15)	29.4 <sup>a</sup> (10)

CG: chronic gastritis; DD: duodenitis II + III; DU: duodenal ulcer; FD: functional dyspepsia; GERD: gastroesophageal reflux disease; NM: normal mucosa; PU: peptic ulcer.

<sup>a</sup> Pangastroduodenitis between (FD + GERD) and (PU + DU)-( $p < 0.05$ ).

**Table 3** Inflammatory map in patients with *Helicobacter pylori*.

Location	NM		CG		SCG		CAG		DD	
	n	% Hp (n)	n	% Hp (n)	n	% Hp (n)	n	% Hp (n)	n	% Hp (n)
Corpus	81	79 (64)	57	88 (50) <sup>a</sup>	44	95 (42)	13	62 (8) <sup>b</sup>	-	-
Antrum	26	50 (13)	112	90 (101) <sup>c</sup>	46	91 (42)	66	89 (59) <sup>d</sup>	-	-
Proximal duodenum (D1)	73	77 (56)	-	-	-	-	-	-	65	89 (58) <sup>e</sup>
Distal duodenum (D2)	104	83 (86)	-	-	-	-	-	-	34	82 (28)

CAG: chronic atrophic gastritis; CG: chronic gastritis; DD: duodenitis II + III; DU: duodenal ulcer; Hp: with *Helicobacter pylori*; NM: normal mucosa; PU: peptic ulcer; SCG: superficial chronic gastritis.

Corpus:

<sup>a</sup> NM vs CG,  $p < 0.0001$  and

<sup>b</sup> SCG vs CAG,  $p < 0.004$ .

<sup>c</sup> Antrum: NM vs CG,  $p < 0.0001$ .

<sup>d</sup> %Hp + with CAG-corpus vs CAG-antrum,  $p < 0.03$ .

<sup>e</sup> D1: NM vs DD,  $p < 0.03$ .

$p < 0.004$ ; and DU vs GERD,  $p < 0.05$ ), as well as at the D2 level (DU vs FD;  $p < 0.02$ ) (Fig. 2). Similarly, at both the D1 and D2 levels, there was a higher frequency of DD vs NM, when comparing the ulcer group with the non-ulcer group (in D1:  $p < 0.003$  and in D2:  $p < 0.01$ ). DD was significantly more frequent in D1 vs D2 in the patients with FD ( $p < 0.007$ ). That finding was also seen in the patients with DU ( $p < 0.05$ ), as well as in the ulcer group and non-ulcer group ( $p < 0.002$

and  $p < 0.02$ , respectively). Taking all 138 study patients into account, the presence of NM and DD in D1 and D2 was clearly related, in such a way that when the mucosa was normal in D1 it was also normal in D2, in 89% of the cases. Inversely, when there was DD in D1, it was also present in D2, in 43% of the cases ( $p < 0.0001$ ); that finding was confirmed, as well, when the 138 patients were divided into the ulcer group and non-ulcer group ( $p < 0.001$ ).

**Pangastritis and pangastroduodenitis.** Pangastroduodenitis was only more frequent in the ulcer group vs the non-ulcer group ( $p < 0.05$ ) (Table 2).

**Helicobacter pylori.** Table 3 shows the gastroduodenal inflammatory map of the 114 patients with *H. pylori*. In all the groups and at all the levels evaluated, the inflammatory map was closely related to the presence of *H. pylori*. Thus, CG of the corpus, CG of the antrum, and DD were significantly related to *H. pylori* colonization (Table 3), and even though it was not significantly predominant in any of the locations, it was higher in the patients with PU, both in the gastric corpus (92.3%) and the gastric antrum (84.6%). On the other hand, *H. pylori* colonization was less frequent when there was CAG in the corpus vs CAG in the antrum (% *H. pylori*+ in CAG-corpus vs CAG-antrum;  $p < 0.03$ ). A relation between the presence of *H. pylori*, CAG, and DD-D1 was observed only between the ulcer group and the non-ulcer group at the level of the antrum ( $p < 0.02$ ).

## Discussion

The prevalence of FD in our patients with dyspepsia was 69.4%, similar to other figures that have been reported,<sup>11-13</sup> in which no gastroduodenal lesions are found in two-thirds of the patients that undergo gastroscopy.<sup>12</sup> Logically, the prevalence of *H. pylori* infection in patients with dyspepsia (84.7%) and in patients with FD (77.9%) was higher than that of the general population of our study patients (52%),<sup>14</sup> although within the reported range.<sup>15-19</sup> According to those data, the prevalence of *H. pylori* in FD is  $\approx 50\%$  higher than in the general population, suggesting a prominence of *H. pylori*, in some aspect of FD pathophysiology and symptoms. That supposition, now reported,<sup>20-24</sup> explains the fact that up to 10% of the patients with FD remain asymptomatic after eradication of the bacterium. This new dyspepsia, no longer called FD, is known as “*H. pylori*-associated dyspepsia”.<sup>20-22</sup> The different prevalence figures that have been reported may be due to the different criteria utilized for defining the patients with *H. pylori*, the varying number of biopsies taken, or to studies conducted on geographically/culturally different populations.<sup>25</sup>

At the level of the corpus, in the 4 subgroups,  $\approx 50\text{-}60\%$  of the patients had NM. According to our data, approximately half of our patients around 50 years of age that present with FD/GERD have NM in the corpus. The remaining patients will present with CG, which will generally be SCG. That coincides with the hypothesis that *H. pylori* infection is acquired in infancy/adolescence that later develops into CG in the corpus and slowly progresses to moderate/severe grades of CG.<sup>1-4</sup> In the corpus, *H. pylori*, together with CG, was present in 45-60% of all the subgroups, except PU (92.3%), confirming the great prominence of *H. pylori* at the level of the corpus, in the development of PU.<sup>1,3</sup> An elevated frequency of CAG does not appear to be necessary for that to occur, given that it was found in only 7.8% of the patients with PU. When CAG of the corpus is extensive, achlorhydria is produced by the massive destruction of parietal cells, changing the habitat, resulting in the decrease/disappearance of *H. pylori*.<sup>1</sup> The low frequency of CAG in PU would favor the high level of colonization found.<sup>1,2</sup>

Our findings concur with the PU pattern described by the Scandinavian groups:<sup>3,4</sup> marked CAG in the antrum/incisura angularis with intestinal metaplasia; and in the corpus, SCG with absent/mild CAG (with no achlorhydria). At the level of the corpus, we consider that the non-ulcer group could have  $\approx 60\%$  NM, parallel to lower colonization ( $< 50\%$ ), and the ulcer group could have high bacterial colonization ( $\geq 60\%$ ) and somewhat more inflammation, with SCG significantly more frequent than CAG, which is in line with results from other studies.<sup>1,26</sup>

There was an increase in CG in the gastric antrum in all the subgroups. The presence of CG was especially high in the patients with PU (92.2%) and DU (85.7%), with CAG in more than two-thirds of the cases and *H. pylori* in more than 60%, with no significant predominance of the bacterium in the antrum vs the corpus, as referred to in other studies.<sup>2,4,15,26</sup> In the DU subgroup, at the level of the antrum, the high frequencies of CAG and *H. pylori* colonization developed parallelly to the previously described pattern at the level of the corpus (predominance of NM or SCG and normal secretion due to the absence or scarcity of atrophic phenomena).<sup>3,4</sup> In summary, at the level of the antrum, there were non-ulcer patients with  $\approx 20\%$  NM, a similar proportion of SCG-CAG, and  $\approx 65\%$  colonization; and PU patients with very little NM ( $< 15\%$ ), predominant CAG (65-70%), and  $\approx 70\%$  bacterial colonization. The elevated frequency of CAG in the antrum of the ulcer group vs the non-ulcer group is also a characteristic reported in other studies,<sup>1,3,4,15,26</sup> suggesting that atrophy at the level of the antrum is a prior condition for the later development of a PU.<sup>3,4</sup> Surprisingly, at the levels of the corpus and the antrum, and in the subgroups of the ulcer group, the frequencies of *H. pylori* infection were similar. However, the percentages of CAG were slightly higher at the level of the antrum vs the corpus. That finding has been explained by a greater immune response and consequent inflammatory reactivity in the presence of *H. pylori*, at the level of the antrum or by the more frequent presence of *H. pylori* strains (CagA gene) that would induce greater production of proinflammatory cytokines.<sup>2,26,27</sup>

There are very few histologic studies of the stomach that complement those of the duodenum, and those that include D2 are exceptional. Logically, the prevalence of DD-D1 in ulcer groups is higher than in FD, with prevalence reports between 36 and 76%<sup>18,25,26,28,29</sup> vs 37% in asymptomatic controls.<sup>29</sup> Our prevalence of DD-D1 in FD (37.7%) is in the lower range of that reported, similar to that of asymptomatic controls, and in line with the results of some European studies.<sup>25,28</sup> The highest prevalences have been reported in studies that utilize semi-quantitative methods for defining DD and that are conducted on Asian populations, which are culturally different from Spanish populations,<sup>18,26</sup> possibly explaining the resulting differences. We encountered no studies for comparing the prevalence of DD-D2 that we found in FD (16.9%), as that segment is not commonly analyzed. An explanation of its low frequency is mentioned further ahead. Therefore, the present study is the first to report the joint prevalence of DD at the D1 and D2 levels in FD. Those data should alert us to the possibility of moderate/severe inflammatory lesions in the duodenum of patients that do not present with ulcer, in those that have

symptoms (FD), as well as those that do not (asymptomatic controls).<sup>29</sup>

As stated above, more than 2/3 of the patients in the ulcer group and more than 3/4 of the patients in the DU subgroup were characterized by presenting DD in D1 and ≈40% cases in D2. In the ulcer group, the presence of DD was significantly related to *H. pylori* and CAG in the antrum, but only in D1. That relation is controversial because it has been confirmed in some studies,<sup>17,18,27,28</sup> but not in others.<sup>30</sup> Regarding the antrum-duodenum conditioned relationship, the progression of the bacterial infection and inflammatory and atrophic state from the antrum to the next level (D1), reproducing the phenomena that previously occurred in the antrum seems logical. For a PU to develop, the previous presence of CAG in the antrum is needed, and for a DU to develop, *H. pylori* colonization of the D1, coming from the antrum, with the later development of DD, is needed. The fact that said relationship appears only at the level of D1, and not D2, could be explained by the changes in the habitat in more distal areas that would impede *H. pylori* infection from developing under adequate conditions. At any rate, said discrepancy could be explained by the very heterogeneous patient groups analyzed or the different methodologies employed for the histologic/bacterial classifications or determinations. In an adequate environment, *H. pylori* colonizes the antrum and induces CG. From there, it moves into D1, where there tends to be sufficient acid load to survive and induce DD, without an associated DU. If acid overload is chronic/intense in D1, adaptive phenomena are produced (gastric metaplasia), favoring *H. pylori* colonization/infection and predisposing to the development of DU. That sequence is not produced in D2 by remaining “stalled” in the DD phase, with no gastric metaplasia, and so DU is exceptional at that level.<sup>3,4,27</sup> The “stalling” of the sequence would take place due to the dilution of the acid and/or the continuous peristalsis that would impede the persistent action of the acid on the mucosa, gastric metaplasia, and bacterial colonization. Our study data adapt well to that entire sequence of events. DD in patients with *H. pylori* that do not present with DU could be the step prior to the development of DU or the step following its recent healing, which would explain why those patients were classified as having FD, in the absence of duodenal biopsies that could have shown the presence of an underlying DD. Those occurrences could justify and explain why dyspeptic symptoms disappear after *H. pylori* eradication in some patients diagnosed with FD,<sup>19–21</sup> and overwhelmingly suggest that the symptoms in the subgroup of patients with FD actually have a duodenal, rather than a gastric, origin.<sup>5,6,23,25,26</sup> In D2, after the inflammatory storm in the corpus-antrum-D1, we recognized an inflammatory calm, with an increase in the frequency of NM of ≈30% (in the non-ulcer group) and ≈100% (in the ulcer group), with respect to that seen in D1. As described above, the finding of NM in D1 almost always conditioned normality in D2 (89%), but if DD was found in D1, DD only occurred in D2 in 43% of the cases. Finally, the fact that only the ulcer group showed a stomach with significantly higher frequencies of pangastritis, DD-D1, and *H. pylori* colonization vs the non-ulcer group, resulted in a significantly more intense gastroduodenal inflammatory map or greater pangastrroduodenitis.

## Financing

No sponsorship of any kind was received for this article.

## Conflict of interests

The authors declare that they have no conflict of interest.

## References

- Sipponen P, Maaros H-I. Chronic gastritis. Scand J Gastroenterol. 2015;50:657–67, <http://dx.doi.org/10.3109/00365521.2015.1019918>.
- Maaros HI, Kekki M, Villako K, et al. The occurrence and extent of *Helicobacter pylori* colonization and antral and body gastritis profiles in an Estonian population sample. Scand J Gastroenterol. 1990;25:1010–7, <http://dx.doi.org/10.3109/00365529008997627>.
- Sipponen P, Varis K, Fräki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol. 1990;25:966–7, <http://dx.doi.org/10.3109/00365529008997621>.
- Kekki M, Sipponen P, Siurala M, et al. Peptic ulcer and chronic gastritis: Their relation to age and sex, and to location of ulcer and gastritis. Gastroenterol Clin Biol. 1990;14:217–23. PMID: 2344909.
- Jung H-K, Talley NJ. Role of the duodenum in the pathogenesis of functional dyspepsia: A paradigm shift. J Neurogastroenterol Motil. 2018;24:345–54, <http://dx.doi.org/10.5056/jnm18060>.
- Wauters L, Ceulemans M, Frings D, et al. Proton pump inhibitors reduce duodenal eosinophilia, mast cells and permeability in patients with functional dyspepsia. Gastroenterology. 2021;160:1521–31, <http://dx.doi.org/10.1053/j.gastro.2020.12.016>.
- Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92, <http://dx.doi.org/10.1053/j.gastro.2016.02.011>.
- Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon consensus. Gut. 2018;67:1352–62, <http://dx.doi.org/10.1136/gutjnl-2017-314722>.
- Whitehead R, Truelove SC, Gear MW. The histological diagnosis of chronic gastritis in fiberoptic gastro-scope biopsy specimens. J Clin Pathol. 1972;25:1–11, <http://dx.doi.org/10.1136/jcp.25.1.1>.
- Whitehead R, Roca M, Meikle DD, et al. The histological classification of duodenitis in fiberoptic biopsy specimens. Digestion. 1975;13:129–36, <http://dx.doi.org/10.1159/000197701>.
- Caballero-Mateos AM, Redondo-Cerezo E. Dyspepsia, functional dyspepsia and Rome IV criteria. Rev Esp Enferm Dig. 2018;110:530–1, <http://dx.doi.org/10.17235/reed.2018.5599/2018>.
- Ford AC, Marwaha A, Lim A, et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:830–7, <http://dx.doi.org/10.1016/j.cgh.2010.05.031>.
- Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: A cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3:252–62, [http://dx.doi.org/10.1016/S2468-1253\(18\)30003-7](http://dx.doi.org/10.1016/S2468-1253(18)30003-7).
- Caballero-Plasencia AM, Sofos-Kontoyannis S, Valenzuela-Barranco M, et al. Epidemiology of dyspepsia in a random Mediterranean population. Prevalence of *Helicobacter pylori*

- infection. *Rev Esp Enferm Dig.* 2000;92:781–92. PMID: 11468786.
15. Fiocca R, Villani L, Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: A morphological approach to the study of ulcerogenesis in man. *Virchows Archiv A Pathol Anat.* 1992;420:489–98, <http://dx.doi.org/10.1007/BF01600253>.
  16. Boixeda D, Gispert JP, Martín-de Argila C, et al. ¿Existe alguna relación entre la sintomatología digestiva y la infección por *H. pylori*? *Rev Esp Enferm Dig.* 1995;87:8–14. PMID: 7727174.
  17. D'costa FG, Dutta S, Patil YV. Histopathology of gastro-duodenal biopsies and *Helicobacter Pylori* infection. *BHJ.* 2007;4902:292–300.
  18. Mirbagheri SA, Khajavirad N, Rakhshani N, et al. Impact of *Helicobacter pylori* infection and microscopic duodenal histopathological changes on Clinical symptoms of patients with functional dyspepsia. *Dig Dis Sci.* 2012;57:967–72, <http://dx.doi.org/10.1007/s10620-011-1960-z>.
  19. Moayyedi P, Soo S, Deeks JJ, et al. Eradication of *Helicobacter pylori* for non-ulcer dyspepsia. *Cochrane Database Syst Rev.* 2011;16:CD002096, <http://dx.doi.org/10.1002/14651858.CD002096>.
  20. Zhao B, Zhao J, Cheng WF, et al. Efficacy of *Helicobacter pylori* eradication therapy on functional dyspepsia: A meta-analysis of randomized controlled studies with 12-month follow-up. *J Clin Gastroenterol.* 2014;48:241–7, <http://dx.doi.org/10.1097/MCG.0b013e31829f2e25>.
  21. Suzuki H, Moayyedi P. *Helicobacter pylori* infection in functional dyspepsia. *Nat Rev Gastroenterol Hepatol.* 2013;10:168–74, <http://dx.doi.org/10.1038/nrgastro.2013.9>.
  22. Pauwels A, Altan E, Tack J. The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease. *Neurogastroenterol Motil.* 2014;26:581–8, <http://dx.doi.org/10.1111/nmo.12305>.
  23. Ronkainen J, Aro P, Walker MM, et al. Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2019;50:24–32, <http://dx.doi.org/10.1111/apt.15308>.
  24. Mezmale L, Coelho LG, Bordin D, et al. Review: Epidemiology of *Helicobacter pylori*. *Helicobacter.* 2020;25:e12734, <http://dx.doi.org/10.1111/hel.12734>.
  25. Phull PS, Price AB, Stephens J, et al. Histology of chronic gastritis with and without duodenitis in patients with *Helicobacter pylori* infection. *J Clin Pathol.* 1996;49:377–80, <http://dx.doi.org/10.1136/jcp.49.5.377>.
  26. Chaudhari AA, Rane SR, Jadhav MV. Histomorphological spectrum of duodenal pathology in functional dyspepsia patients. *J Clin Diag Res.* 2017;11:EC01–4, <http://dx.doi.org/10.7860/JCDR/2017/25297.9985>.
  27. Genta RM, Kinsey RS, Singhal A, et al. Gastric foveolar metaplasia and gastric heterotopia in the duodenum: No evidence of an etiologic role for *Helicobacter pylori*. *Human Pathology.* 2010;41:1593–600, <http://dx.doi.org/10.1016/j.humpath.2010.04.010>.
  28. Jönsson KA, Gotthard R, Bodemar G, et al. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. *Scand J Gastroenterol.* 1989;24:385–95, <http://dx.doi.org/10.3109/00365528909093064>.
  29. Lee MJ, Jung HK, Lee KE, et al. Degranulated eosinophils contain more fine nerve fibers in the duodenal mucosa of patients with functional dyspepsia. *J Neurogastroenterol Motil.* 2019;25:212–21, <http://dx.doi.org/10.5056/jnm18176>.
  30. Wyatt JL, Rathbone BJ, Sobala GM, et al. Gastric epithelium in the duodenum: its association with *Helicobacter pylori* and inflammation. *J Clin Pathol.* 1990;43:981–6, <http://dx.doi.org/10.1136/jcp.43.12.981>.